Aspirin and Ticagrelor Dosing in Acute Myocardial Infarction
In acute MI, give aspirin 162-325 mg loading dose (chewed, non-enteric coated) immediately on presentation, followed by 75-100 mg daily maintenance, and ticagrelor 180 mg loading dose followed by 90 mg twice daily. 1
Loading Doses - Administer Immediately on Presentation
Aspirin
- Loading dose: 162-325 mg orally 1
- Must be chewed (non-enteric coated) to achieve faster onset of antiplatelet action 1
- Give this loading dose even if the patient is already on chronic aspirin therapy 1, 2
- Timing: As soon as possible on presentation, regardless of whether invasive or conservative strategy is planned 1
Clinical Pearl: Recent evidence shows that patients with acute MI already on chronic aspirin who receive a loading dose (200-500 mg) achieve 6-fold greater thromboxane A2 suppression compared to continuing 100 mg alone, with 53% having inadequate platelet inhibition without the loading dose 2. This translates to better left ventricular function.
Ticagrelor
- Loading dose: 180 mg orally 1
- Timing: Should be administered as early as possible, ideally at first medical contact 3, 4
- Prehospital administration is superior: When given by EMS before hospital arrival, ticagrelor achieves better TIMI 3 flow (91.4% vs 82.2%), better ST-segment resolution (76.3% vs 64.5%), and reduced 30-day MACE (5.4% vs 11.2%) without increased bleeding 3
Maintenance Doses
Aspirin
- 75-100 mg daily (non-enteric coated) 1
- Critical: When using ticagrelor, aspirin must be ≤100 mg daily 1
- Post-hoc analysis of the PLATO trial showed worse outcomes with higher aspirin doses when combined with ticagrelor 1
- Full-dose aspirin (300-325 mg daily) for 30 days after loading was not superior to low-dose and caused more bleeding 1
Ticagrelor
Timing Algorithm
At first medical contact (ideally prehospital via EMS):
- Aspirin 162-325 mg (chewed)
- Ticagrelor 180 mg
Starting next day through 12 months:
- Aspirin 75-100 mg daily
- Ticagrelor 90 mg twice daily
After 12 months: Typically transition to aspirin monotherapy (though this is beyond the scope of acute dosing)
Evidence Strength
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide Class 1 (strong) recommendations for:
- P2Y12 inhibitor plus aspirin in all ACS patients (Level A evidence) 1
- Ticagrelor or prasugrel over clopidogrel in STEMI with primary PCI (Level B-R evidence) 1
- Ticagrelor in NSTE-ACS managed conservatively (Level B-R evidence) 1
Common Pitfalls to Avoid
- Don't skip the aspirin loading dose in patients already on aspirin - they still need it for adequate platelet inhibition 2
- Don't use high-dose aspirin maintenance with ticagrelor - keep aspirin ≤100 mg daily to avoid worse outcomes 1
- Don't delay ticagrelor until catheterization - prehospital administration improves reperfusion and outcomes 3, 4
- Don't use enteric-coated aspirin for loading - it delays onset of action 1
Special Considerations
Contraindication: Do not use ticagrelor with strong CYP3A4 inhibitors like itraconazole - this is contraindicated per FDA labeling 6
Bleeding risk: While ticagrelor increases dyspnea as a side effect, major bleeding rates are acceptable when used appropriately. Prehospital administration does not significantly increase bleeding (4.39% vs 1.39%, p=0.142) 4.